Synlogic Therapeutics

Cambridge, United States Founded: 2013 • Age: 13 yrs
Engineered microbes are developed as programmable therapeutics for metabolic disorders.
Request Access

About Synlogic Therapeutics

Synlogic Therapeutics is a company based in Cambridge (United States) founded in 2013 by James J Collins.. Synlogic Therapeutics has raised $34.4 million across 9 funding rounds from investors including Gates Foundation, HHS and Orbimed. The company has 1 employees as of December 31, 2024. Synlogic Therapeutics offers products and services including Synthetic Biotics. Synlogic Therapeutics operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Amyris and Rhythm Pharmaceuticals, among others.

  • Headquarter Cambridge, United States
  • Employees 1 as on 31 Dec, 2024
  • Founders James J Collins
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Synlogic, Inc.
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Healthcare Products & Supplies
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
    $8 K
    -99.76
    as on Dec 31, 2024
  • Net Profit
    $-23.36 M
    61.88
    as on Dec 31, 2024
  • EBITDA
    $-14.48 M
    70.96
    as on Dec 31, 2024
  • Total Equity Funding
    $34.4 M (USD)

    in 9 rounds

  • Latest Funding Round
    $80 M (USD), Post-IPO

    Jun 18, 2019

  • Investors
  • Employee Count
    1

    as on Dec 31, 2024

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of Synlogic Therapeutics

Synlogic Therapeutics is a publicly listed company on the NASDAQ with ticker symbol SYBX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: NASDAQ · Ticker: SYBX . Sector: Health technology · USA

Products & Services of Synlogic Therapeutics

Synlogic Therapeutics offers a comprehensive portfolio of products and services, including Synthetic Biotics. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Engineered microbes to treat metabolic diseases like PKU.

People of Synlogic Therapeutics
Headcount 50-200
Employee Profiles 12
Board Members and Advisors 12
Employee Profiles
People
Mary Beth Dooley
Vice President, Head Of Finance
People
Antoine Awad
COO
People
Caroline B. Kurtz
Chief Development Officer
People
Brendan St. Amant
Head, Legal

Unlock access to complete

Funding Insights of Synlogic Therapeutics

Synlogic Therapeutics has successfully raised a total of $34.4M across 9 strategic funding rounds. The most recent funding activity was a Post-IPO round of $80 million completed in June 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 9
  • Last Round Post-IPO — $80.0M
  • First Round

    (01 Jul 2013)

  • Investors Count 12
Date Amount Transaction Name Valuation Lead Investors Investors
Jun, 2019 Amount Post-IPO - Synlogic Therapeutics Valuation

investors

May, 2017 Amount Post-IPO - Synlogic Therapeutics Valuation

investors

Feb, 2016 Amount Post-IPO - Synlogic Therapeutics Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Synlogic Therapeutics

Synlogic Therapeutics has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include Gates Foundation, HHS and Orbimed. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Diversified investment, VC & financial advisory firm
Founded Year Domain Location
Private equity and hedge fund investments in healthcare are managed.
Founded Year Domain Location
VC Firm investing in geographies such as the US
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Synlogic Therapeutics

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Synlogic Therapeutics

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Synlogic Therapeutics Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Synlogic Therapeutics

Synlogic Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Amyris and Rhythm Pharmaceuticals, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
mRNA-based therapeutics for diseases including cancer and infections are developed.
domain founded_year HQ Location
Therapeutics for genetic diseases are developed through targeted interventions.
domain founded_year HQ Location
Gene therapies for rare diseases including retinal dystrophies are developed.
domain founded_year HQ Location
Developer of renewable products for industrial solutions
domain founded_year HQ Location
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
domain founded_year HQ Location
Developer of drugs for treating rare and autoimmune diseases
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Synlogic Therapeutics

Frequently Asked Questions about Synlogic Therapeutics

When was Synlogic Therapeutics founded?

Synlogic Therapeutics was founded in 2013.

Where is Synlogic Therapeutics located?

Synlogic Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.

Is Synlogic Therapeutics a funded company?

Synlogic Therapeutics is a funded company, having raised a total of $34.4M across 9 funding rounds to date. The company's 1st funding round was a Post-IPO of $40M, raised on Jul 01, 2013.

How many employees does Synlogic Therapeutics have?

As of Dec 31, 2024, the latest employee count at Synlogic Therapeutics is 1.

What is the annual revenue of Synlogic Therapeutics?

Annual revenue of Synlogic Therapeutics is $8K as on Dec 31, 2024.

What does Synlogic Therapeutics do?

Synlogic Therapeutics was founded in 2013 in Cambridge, Massachusetts, within the biotechnology sector. A proprietary platform is employed to engineer microbes for drug production, targeting urea cycle disorders and phenylketonuria. Standardized interchangeable parts and gene-circuit controls are integrated to design synthetic biology solutions. Microbes are transformed into symbiotic living therapeutics that respond to pathophysiological signals in the human body, facilitating targeted treatments.

Who are the top competitors of Synlogic Therapeutics?

Synlogic Therapeutics's top competitors include Moderna, Spark Therapeutics and BridgeBio.

What products or services does Synlogic Therapeutics offer?

Synlogic Therapeutics offers Synthetic Biotics.

Is Synlogic Therapeutics publicly traded?

Yes, Synlogic Therapeutics is publicly traded on NASDAQ under the ticker symbol SYBX.

Who are Synlogic Therapeutics's investors?

Synlogic Therapeutics has 12 investors. Key investors include Gates Foundation, HHS, Orbimed, Atlas Venture, and Perceptive Advisors.

What is Synlogic Therapeutics's ticker symbol?

The ticker symbol of Synlogic Therapeutics is SYBX on NASDAQ.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available